Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
12–74
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%)
Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes.
Episodic (on-demand) treatment regimen prior to screening
At least 6 acute bleeding episodes during the 6-month period prior to screening
You may not be if
Known coronary artery, thrombotic, or ischemic disease
Concomitant treatment with activated prothrombin complex concentrate
Clareo Health | PF-06741086 Long-term Treatment in Severe Hemophilia
